Journal
ATHEROSCLEROSIS
Volume 227, Issue 1, Pages 72-78Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2012.12.007
Keywords
SAA; NF-kappa B; PPAR gamma; FPRL-1; TLR4
Funding
- National Medical Research Council, Singapore [NMRC/1155/2008, NMRC/EDG/1041/2011]
- National University of Singapore
Ask authors/readers for more resources
Serum amyloid A (SAA) is an acute phase protein whose expression increases markedly during bacterial infection, tissue damage, and inflammation. The potential beneficial roles of SAA include its involvement in the reverse cholesterol transport and possibly extracellular lipid deposition at sites of inflammation and tissue repair. It is an attractive therapeutic target for the treatment of atherosclerosis. Peroxisome proliferator-activated receptor gamma (PPAR gamma) plays a major regulatory role in adipogenesis, and the expression of genes involved in lipid metabolism. Activation of PPAR gamma leads to multiple changes in gene expression, some of which are believed to be atherogenic while others are antiatherogenic. In this study, we demonstrated that SAA upregulated COX-2 expression and induced PPAR gamma activity through NF-kappa B pathway. The effect of SAA on NF-kappa B activity is mediated by FPRL-1 and TLR4. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available